Listed

Arbutus Biopharma Corp: Form 10-Q for the period ended Mar 31, 2017

Filed with the SEC on May 4, 2017 and accepted by EDGAR at May 4, 2017, 17:23 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-01-01 to 2017-03-31$235.0kus-gaap:Revenues
Research and development3 months2017-01-01 to 2017-03-31$13.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-01-01 to 2017-03-31−$18.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-01-01 to 2017-03-31$42.0kus-gaap:InterestExpense
Net income3 months2017-01-01 to 2017-03-31−$18.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-01-01 to 2017-03-31−$0.34us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2017-01-01 to 2017-03-31−$17.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2017-01-01 to 2017-03-31$3.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-03-31$29.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-03-31$120.3mus-gaap:AssetsCurrent
Total assetsAt period end2017-03-31$268.1mus-gaap:Assets
Current liabilitiesAt period end2017-03-31$10.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-03-31$79.0mus-gaap:Liabilities
Shareholders' equityAt period end2017-03-31$189.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-17-004968. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.